100 related articles for article (PubMed ID: 17362751)
1. Basiliximab improves graft survival in renal transplant recipients with delayed graft function.
Gonçalves LF; Ribeiro AR; Berdichevski R; Joelsons G; Proença MC; Manfro RC
Transplant Proc; 2007 Mar; 39(2):437-8. PubMed ID: 17362751
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
[TBL] [Abstract][Full Text] [Related]
3. Basiliximab (Simulect) in renal transplantation with high risk for delayed graft function.
Fernandez Rivera C; Alonso Hernandez A; Villaverde Verdejo P; Oliver García J; Valdés Cañedo F
Transplant Proc; 2005 Apr; 37(3):1435-7. PubMed ID: 15866629
[TBL] [Abstract][Full Text] [Related]
4. Induction with basiliximab in renal transplantation.
Ferrer F; Machado S; Alves R; Macário F; Bastos C; Roseiro A; Mota A
Transplant Proc; 2010 Mar; 42(2):467-70. PubMed ID: 20304166
[TBL] [Abstract][Full Text] [Related]
5. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency.
Verna EC; Farrand ED; Elnaggar AS; Pichardo EM; Balducci A; Emond JC; Guarrera JV; Brown RS
Transplantation; 2011 Jun; 91(11):1254-60. PubMed ID: 21617588
[TBL] [Abstract][Full Text] [Related]
6. Recovery of graft function in pediatric kidney transplantation is not affected by delayed introduction of cyclosporine.
Cransberg K; Bouts AH; Cornelissen EA; Lilien MR; Van Hoeck KJ; Hop WC; Nauta J
Transplantation; 2008 Nov; 86(9):1199-205. PubMed ID: 19005400
[TBL] [Abstract][Full Text] [Related]
7. Ten-year follow-up of basiliximab induction therapy for live-donor kidney transplant: a prospective randomized controlled study.
Sheashaa HA; Bakr MA; Rashad RH; Ismail AM; Sobh MA; Ghoneim MA
Exp Clin Transplant; 2011 Aug; 9(4):247-51. PubMed ID: 21819369
[TBL] [Abstract][Full Text] [Related]
8. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
9. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients.
Ganschow R; Grabhorn E; Schulz A; Von Hugo A; Rogiers X; Burdelski M
Pediatr Transplant; 2005 Dec; 9(6):741-5. PubMed ID: 16269045
[TBL] [Abstract][Full Text] [Related]
11. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
12. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
Thistlethwaite JR; Nashan B; Hall M; Chodoff L; Lin TH
Transplantation; 2000 Sep; 70(5):784-90. PubMed ID: 11003358
[TBL] [Abstract][Full Text] [Related]
13. The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study.
Naderi GH; Mehraban D; Ganji MR; Jafarpouriani M; Latif AH
Transplant Proc; 2009 Sep; 41(7):2768-71. PubMed ID: 19765430
[TBL] [Abstract][Full Text] [Related]
14. Induction with basiliximab plus thymoglobulin is effective and safe in old-for-old renal transplantation: six-month results of a prospective clinical study.
Favi E; Gargiulo A; Spagnoletti G; Salerno MP; Silvestrini N; Valente I; Citterio F
Transplant Proc; 2010 May; 42(4):1114-7. PubMed ID: 20534237
[TBL] [Abstract][Full Text] [Related]
15. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
[TBL] [Abstract][Full Text] [Related]
16. Induction treatment with low-dose thymoglobulin or basiliximab in renal transplants from older donors.
Gavela Martínez E; Sancho Calabuig A; Escudero Quesada V; Avila Bernabeu AI; Beltrán Catalán S; Morales García AI; Crespo Albiach JF; Pallardó Mateu LM
Transplant Proc; 2008 Nov; 40(9):2900-2. PubMed ID: 19010141
[TBL] [Abstract][Full Text] [Related]
17. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study.
Sheashaa HA; Bakr MA; Ismail AM; Gheith OE; El-dahshan KF; Sobh MA; Ghoneim MA
Am J Nephrol; 2005; 25(3):221-5. PubMed ID: 15908741
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
[TBL] [Abstract][Full Text] [Related]
19. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
[TBL] [Abstract][Full Text] [Related]
20. Single-Dose Basiliximab Induction in Low-Risk Renal Transplant Recipients.
Cunningham KC; Hager DR; Fischer J; D'Alessandro AM; Leverson GE; Kaufman DB; Djamali A
Pharmacotherapy; 2016 Jul; 36(7):823-9. PubMed ID: 27265620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
